Efficacy and safety of uncovered self‐expandable metal stents for distal malignant biliary obstruction in unresectable non‐pancreatic cancer

Abstract

AbstractObjectivesThe efficacy of uncovered self‐expandable metal stents (UCSEMS) versus fully covered self‐expandable metal stents for distal malignant biliary obstruction remains controversial. Additionally, the heterogeneity of the disease conditions has been indicated in previous studies because pancreatic and non‐pancreatic cancers have different characteristics in clinical course. Therefore, the etiology of biliary obstruction necessitates investigations stratified by primary disease. This study aimed to evaluate the outcomes of UCSEMS, specifically for non‐pancreatic cancer‐induced distal malignant biliary obstruction.MethodsWe conducted a single‐center retrospective review to evaluate the time to recurrent biliary obstruction and frequency of adverse events (AEs) in patients receiving UCSEMS for unresectable non‐pancreatic cancer‐induced malignant biliary obstruction.ResultsOverall, 32 patients were enrolled in the study between January 2016 and December 2023. The median time to recurrent biliary obstruction was 140 days. AE rates were low at 3.1% for both pancreatitis and cholecystitis, suggesting a potential benefit of UCSEMS in reducing post‐procedural AEs.ConclusionUCSEMS may reduce the risk of post‐procedural AEs and should be considered in patients at high risk of post‐endoscopic retrograde cholangiopancreatography pancreatitis. However, the patency period may be shorter, necessitating future comparative research with fully covered self‐expandable metal stents to determine the optimal stent choice.